Digital health and disruption in diabetes

As the web of digital health participants evolves and becomes more complex, the race will be on to devise new ways to achieve better patient outcomes, reduce healthcare spend and improve customer experiences. Life sciences companies are well-positioned to identify those digital health opportunities that most closely align with not only patients’ needs, but their own long-term growth objectives. 

This paper and those that follow are intended to serve as guides for life sciences organizations seeking to determine where the opportunities and threats lie as digital health becomes more mature and ubiquitous. It is critical that life sciences companies seize opportunities to build, buy or partner to create digital health solutions that span the patient journey, before they are overtaken by technology leaders seeking to do the same.

Despite some progress toward individualized treatment regimens and a very competitive market with a variety of first-line and adjunctive treatments, no diabetes therapy is disease-modifying at present. Therefore, life sciences companies have a unique opportunity to either take the lead or partner with technology companies and healthcare providers to create digital health solutions that make life easier throughout the complex and often onerous diabetes patient journey.